Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
1 Year
—
84x
Grew
—
—
Shrank
—
1 Year
Score—
Net Growth84x
Net TrendGrew
Net Income Consistency—
Rev Growth—
Rev TrendShrank
Revenue Consistency—
5 Years
5.3
106x
60%
—
-100.00%
Never
—
5 Years
Score5.3
Net Growth106x
Net Trend60%
Net Income Consistency—
Rev Growth-100.00%
Rev TrendNever
Revenue Consistency—
Enlivex Therapeutics Ltd fundamental performance
Between 2020 and 2025, revenue declined from $ 2M to $ 0.00 and net income went from -$ 11M to $ 1.23B. Revenue increased in 0 of those 5 years; net income in 3.
Enlivex Therapeutics Ltd currently holds a 5-year HDB Score of 5.3 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 1.84 | — |
1 Year2025-08-12 | $ 23.55 | -92.19% |
5 Years2021-08-12 | $ 158.85 | -98.84% |
10 Years2016-08-12 | $ 1.01K | -99.82% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | 10 Years2016-08-12 |
|---|---|---|---|---|
| Price | $ 1.84 | $ 23.55 | $ 158.85 | $ 1.01K |
| Return | — | -92.19% | -98.84% | -99.82% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2025 | $ 0.00 | $ 1.23B | $ 5M |
| 2024 | $ 0.00 | -$ 15M | $ 23M |
| 2023 | $ 0.00 | -$ 29M | $ 27M |
| 2022 | $ 0.00 | -$ 31M | $ 50M |
| 2021 | $ 0.00 | -$ 14M | $ 84M |
| 2020 | $ 2M | -$ 11M | $ 35M |
| 2019 | $ 0.00 | -$ 9M | $ 12M |
| 2018 | $ 0.00 | -$ 4M | $ 9M |
| 2017 | $ 0.00 | -$ 5M | $ 3M |
| 2016 | $ 0.00 | -$ 16M | $ 9M |
| 2015 | -$ 15M | $ 19M | |
| 2014 | -$ 7M | $ 32M | |
| 2013 | -$ 1M | $ 270K | |
| 2012 | -$ 229K | $ 146K | |
| 2007 | $ 18M | ||
| 2006 | $ 17M | ||
| 2005 | $ 25M | ||
| 2004 | $ 14M | ||
| 2003 | $ 13M | ||
| 2002 | $ 18M | ||
| 2001 | $ 14M | ||
| 2000 | $ 3M |
Explore beyond ENLV
You're looking at Enlivex Therapeutics Ltd. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
